Boston Scientific Corporation (BSX) is gaining investor attention, including Marshall Wace LLP, which holds nearly $792 ...

Boston Scientific has shown high revenue and EPS growth rates in recent years. See why I recommend a hold rating for BSX stock.

Boston Scientific’s stock surged 40.6% in the past year, far outpacing the broader market. This growth stems from strong ...

The DCB looks good in select cases, but given its high price tag, exactly when to use it is still up for discussion, say ...

Boston Scientific (NYSE:BSX – Get Free Report) was downgraded by StockNews.com from a “buy” rating to a “hold” rating in a ...

In a wide manufacturing room with white walls and low ceilings, Boston Scientific employees combine components into finished ...

The global Bioabsorbable Stents Market, valued at US$ 375.5 million in 2022, is expected to grow at a compound annual growth ...

The intracranial stents market is experiencing rapid growth, fueled by the rising incidence of strokes, aneurysms, and ...

India Coronary Stents Market is estimated to be valued at US$ 1,303.5 million in 2023 and is expected to exhibit a CAGR of 13.2 % by (2023-2030). Mr. Shah Coherent Market Insights Pvt. Ltd. +1 ...

Boston Scientific Corporation ( NYSE: BSX) TD Cowen 45th Annual Healthcare Conference March 4, 2025 9:10 AM ET Dan Brennan - Chief Financial Officer Ken Stein - Chief Medical Officer Art Butcher - ...

(RTTNews) - Boston Scientific Corp. (BSX), Monday announced its decision to acquire SoniVie Ltd., a privately held medical device company that has developed the TIVUS Intravascular Ultrasound System.

StockNews.com upgraded shares of Boston Scientific (NYSE:BSX – Free Report) from a hold rating to a buy rating in a research report sent to investors on Friday. A number of other equities analysts ...